18 related articles for article (PubMed ID: 8261671)
1. Phorbol myristate acetate (PMA) reverses inhibition of interleukin-2 production by T lymphocytes of patients with systemic lupus erythematosus.
Sierakowski S; Kucharz EJ
Med Interne; 1988; 26(1):67-73. PubMed ID: 3261032
[TBL] [Abstract][Full Text] [Related]
2. Enhanced CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus.
Stekman IL; Blasini AM; Leon-Ponte M; Baroja ML; Abadi I; Rodriguez MA
Arthritis Rheum; 1991 Apr; 34(4):459-67. PubMed ID: 1826426
[TBL] [Abstract][Full Text] [Related]
3. Responsiveness of systemic lupus erythematosus T cells to signals provided through LCA T200 (CD45) and T1 (CD5) antigens.
Martorell J; Font J; Rojo I; Vilella R; Ingelmo M; Vives J
Clin Exp Immunol; 1989 Nov; 78(2):172-6. PubMed ID: 12412744
[TBL] [Abstract][Full Text] [Related]
4. Impaired T-cell activation in patients with systemic lupus erythematosus.
Sierakowski S; Kucharz EJ; Lightfoot RW; Goodwin JS
J Clin Immunol; 1989 Nov; 9(6):469-76. PubMed ID: 2517125
[TBL] [Abstract][Full Text] [Related]
5. Effect of phorbol myristate acetate on T cell colony formation, interleukin-2 (IL-2) receptor expression and IL-2 production by cells from patients at all stages of HIV infection.
Allouche M; Lunardi-Iskandar Y; Varela-Millot C; Itzhaki M; Cornuet P; Meyer P; Jasmin C; Georgoulias V
Clin Exp Immunol; 1990 Aug; 81(2):200-6. PubMed ID: 1696861
[TBL] [Abstract][Full Text] [Related]
6. T lymphocytes from patients with systemic lupus erythematosus show increased response to interleukin-2 after costimulation with OKT3 monoclonal antibody and phorbol esters.
Blasini AM; Stekman IL; Gonzalez F; Tositti ML; Rodriguez MA
Clin Immunol Immunopathol; 1994 Jan; 70(1):66-72. PubMed ID: 8261671
[TBL] [Abstract][Full Text] [Related]
7. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE.
Tsokos GC; Nambiar MP; Tenbrock K; Juang YT
Trends Immunol; 2003 May; 24(5):259-63. PubMed ID: 12738420
[No Abstract] [Full Text] [Related]
8. T cells as therapeutic targets in SLE.
Crispín JC; Kyttaris VC; Terhorst C; Tsokos GC
Nat Rev Rheumatol; 2010 Jun; 6(6):317-25. PubMed ID: 20458333
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
